Related Experiment Videos
[Antimycotic drugs under continuous renal replacement therapy]
1Klinik für Chirurgie, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, D-23538 Lübeck, Germany. elke.muhl@medinf.uni-luebeck.de
Mycoses
|April 14, 2005
Summary
For critically ill patients on continuous renal replacement therapy (CRRT), fluconazole dosing needs adjustment. Higher doses may be required due to increased drug clearance, necessitating therapeutic drug monitoring to ensure effective antifungal treatment.
Area of Science:
- Pharmacology
- Nephrology
- Critical Care Medicine
Context:
- Critically ill patients often develop acute renal failure requiring continuous renal replacement therapy (CRRT).
- Antimycotic agent elimination is complex in CRRT patients, influenced by therapy parameters and drug properties.
- Standard dosing of antifungals may be inadequate in this population.
Purpose:
- To evaluate the impact of CRRT on the elimination of various antimycotic agents.
- To determine the specific pharmacokinetic considerations for fluconazole in CRRT patients.
- To provide guidance on optimizing fluconazole therapy in this vulnerable patient group.
Summary:
- High protein binding, high molecular weight, and low renal clearance indicate poor elimination by CRRT for drugs like amphotericin B, caspofungin, itraconazole, and voriconazole.
- Fluconazole, however, can be significantly cleared by CRRT, potentially requiring higher daily doses (e.g., 800 mg or more) than in patients with normal renal function.
- Accurate fluconazole dosing in CRRT patients necessitates therapeutic drug monitoring to prevent underdosing and treatment failure.
Impact:
- Highlights the need for individualized dosing strategies for fluconazole in CRRT patients.
- Emphasizes the importance of therapeutic drug monitoring for antifungals in critical care settings.
- Informs clinical practice regarding the management of fungal infections in patients with acute renal failure undergoing CRRT.